Management of secondary hyperparathyroidism

Therapeutic Apheresis and Dialysis

Volumn 9, Issue SUPPL. 1, 2005, Pages

  Cunningham, John ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Calcimimetics; Chronic kidney disease; Hyperparathyroidism; Vascular calcification; Vitamin D analogs

Indexed keywords

22 OXACALCITRIOL; ALCOHOL; ALFACALCIDOL; ALUMINUM; AMINOGLYCOSIDE DERIVATIVE; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM SENSING RECEPTOR; CINACALCET; DOXERCALCIFEROL; LANTHANUM; MAGNESIUM; PARATHYROID HORMONE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; PHOSPHORUS; R 568; SEVELAMER; VITAMIN D;

ARTERY CALCIFICATION; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE COURSE; DRUG COST; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG POTENCY; HEART DEATH; HEMODIALYSIS PATIENT; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; INTERMETHOD COMPARISON; PARATHYROID CELL; PARATHYROID GLAND; PARATHYROID HORMONE BLOOD LEVEL; PARATHYROID HYPERPLASIA; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; SKELETON; TREATMENT OUTCOME; UPREGULATION; ARTICLE; BLOOD;

CALCIUM; HUMANS; HYPERPARATHYROIDISM, SECONDARY; PHOSPHORUS;

EID: 33645247448     PISSN: 17449979     EISSN: 17449987     Source Type: Journal    
DOI: 10.1111/j.1744-9987.2005.00310.x     Document Type: Conference Paper

References (12)

1. Eknoyan G, Levin A, Levin NW. Bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003;42:1-201.
2. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
3. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T. Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 1999;33:287-93.
4. Goodman WG, Goldin J, Kuizon BD et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000;342:1478-83.
5. Block GA et al. J Am Soc Nephrol 2003;14:474A.
6. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y. Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 1993;92:1436-43.
7. Malberti F, Farina M, Imbasciati E. The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 1999;14:2398-406.
8. Brown EM, Gamba G, Riccardi D et al. Cloning and characterization of an extracellular Ca (2+) -sensing receptor from bovine parathyroid. Nature 1993;366:575-80.
9. Block GA, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 2004;350:1516-25.
10. Cunningham J, Danese M, Olson K, Klassen P, Chertow C. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture and health-related quality of life in secondary hyperparathyroidism. Kidney International 2005.
11. Chertow GM, Burke SK, Raggi P. Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-52.
12. Shiizaki K, Negi S, Hatamura I et al. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats. J Am Soc Nephrol 2005;16:97-108.